Nominations will open on 15 August 2017 and close on Friday 27 October 2017.
Over the past 25 years the Clunies Ross Awards (CRA) have recognised contributions by dedicated individuals to the application of technology for the benefit of Australia. In recognition of the complex nature of such activities the Clunies Ross Awards are awarded in three categories with a single winner in each category.
For those who have played a leadership role in the translation of a technology-based product or service that has led to financial success and demonstrated impact for Australia, and in which they have personally had a significant input in the inventorship or development of the technology. Such a person would typically have business responsibility as a CEO or a senior manager and may be working in either an early stage SME or a mature company environment.
Typically this would be an entrepreneurial person leading an activity that is disrupting well established vendors or commercialising new opportunities through innovative use of new technologies.
For those who have been responsible for the development and adoption of a technology and for sharing their knowledge leading to commercialisation, for example by licensing with a financially successful outcome.
Typically this could be a researcher or developer in a Public Funded Research Organisation, university or private company who has successfully passed his or her product/invention/service to a third party to commercialise and has generated significant revenue to the person and /or organisation they are associated with.
For those who have been responsible for the development and adoption of a technology that has significantly improved societal and/or industry capabilities. In this case the primary outcome is not a financial benefit but has measurable broad community or industry impact.
Typically this could be a researcher or developer in a Public Funded Research Organisation, university or private company, where the outcome is in the form of industry development, or measureable improvement in community well-being or sustainability measures. Examples could include technologies that improve remote monitoring of agriculture/ecosystems, or improved access to remote learning and health care.
The Australian Academy of Technology and Engineering administers the award which will be presented at the ATSE Innovation Dinner at the annual ATSE National Technology Challenges Dialogue.
Professor Andrew Wilks FTSE has made key contributions to the development of a successful new drug for the treatment of haematological malignancies such as Idiopathic Myelofibrobrosis, a highly malignant condition caused by the inappropriate activation of JAK2, a cellular enzyme he discovered in 1989. The story spans nearly 30 years, from his discovery of this important cellular enzyme, through to the design and development in 2005 of a new drug, known as Momelotinib, that has recently successfully completed Phase 3 trials to treat patients with this and other diseases.
Professor Wilks, now co-founder and Executive Chairman of the SYNthesis med chem Group, has completed a rare “trifecta” – discovering and patenting a number of important drug discovery targets (JAK1 and JAK2); founding and raising funds for the establishment of one of Australia’s most successful biotech company, Cytopia (later merged into Canada's YM BioSciences and ultimately sold to Gilead Sciences); and co-inventing and leading the team that delivered Momelotinib.
Improvised explosive devices (IEDs) take a daily physical and emotional toll in Afghanistan and other conflict zones. Mr Smart has researched radio-activated IEDs and developed novel counter-IED units to protect individual Australian Defence Force (ADF) soldiers and vehicles as well as coalition partners.
Mr Smart is Group Leader, Communications and Electronic Warfare, at the Defence Science and Technology Group, based at Edinburgh, South Australia. In this role he led the IED Countermeasure system development team that developed four unique protection systems and devices then took them through commercialisation with an estimated benefit of $61 million. The products showcase how Australia’s cutting-edge technological development can make an impact on the global stage.
He has more than 30 years’ expertise in electronic warfare and is credited with having a profound impact on the cultural environment within the defence scientific community through leading and managing teams across large multi-disciplinary activities.
Prof Mike Xie FTSE, Director of the Centre for Innovative Structures and Materials at RMIT University, has made significant contributions to the original development and subsequent adoption of a technology known as Evolutionary Structural Optimisation (ESO) and Bidirectional ESO (BESO).
This technology has been used to design many landmark buildings and other novel products around the world. Major companies in Australia including Arup, Boeing and Thales have collaborated with Professor Xie to design light-weight and high-performance structures and materials using ESO/BESO.
The original ESO technique, first proposed by Professor Xie’s team in 1992, was based on the simple concept of gradually removing inefficient material from a structure so that the resulting shape would evolve towards the optimum. A more robust technique known as BESO, which was introduced by Professor Xie’s team a few years later, allows material to be removed and added simultaneously by redistributing the under-utilised material to the most needed locations.
Enhancing Australia's prosperity through technology and innovation